Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesJustification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials
Investigational New Drugs, 10/08/09
Penel N et al. – Few parameters influence the accrual time of dose–escalation phase–1 trials. Real first–in–man phase 1 studies based on starting dose estimated from animal toxicological data require longer accrual time.
Related Articles
Treatment of polymyalgia rheumatica
Archives of Internal Medicine, 11/11/09
Relevance Score: 68%
Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma
American Journal of Clinical Oncology, 10/06/09
Relevance Score: 68%
Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism
Osteoporosis International, 10/30/09
Relevance Score: 66%
Take multiple factors into account when choosing the best opioid for pain therapy in paediatric palliative care
Drugs & Therapy Perspectives, 10/16/09
Relevance Score: 66%
One Dose of H1N1 Vaccine Immunogenic in High Percentage of Pregnant Women. No Safety Concerns Reported During Ongoing Clinical Trial
American Family Physician, 11/06/09
Relevance Score: 65%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
A Phase I Study of Pegylated Liposomal Doxorubicin and Irinotecan in Patients with Solid Tumors
Chemotherapy, 12/11/09
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial
The Lancet - Early Online Publication, 12/11/09
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin
Cancer Chemotherapy and Pharmacology, 12/11/09
Sponsor
Article Search
Sponsor
Sponsor